-', FORM RTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO. PH-7382-NP

**APPLICATION NO. 10/650,358** 

**APPLICANT** 

Michael G. Yang

(Use several sheets if necessary)

INFORMATION DISCLOSURE CUTATION

DEC 1			r 1 5 CIB	5 2003 FILING DATE 27 Aug 2003							
		THE STATE OF THE S	برائي المجارية	S. PATEN	IT DOCUMENTS		<del></del>				
EXAMINE R INITIAL		DOCUMENT NUMBERHADE		······································		CLASS SUBCLAS		ASS	SS FILING DATE		
<del></del>	AA										
	AB										
FOREIGN PATENT DOCUMENTS											
	AC	DOCUMENT NUMBER	DATE	OFFICE			CLASS	SUBCLASS	TR/ YES	TRANSLATION YES NO	
G	AD	WO 00/07995	17 Feb 2000	DU PONT PHARMACEUTICALS CO		ALS CO.					
B	AE	WO 01/77086	18 Oct 2001	DU PON	T PHARMACEUTIC	ALS CO.					
G	AF	WO 00/38618	6 July 2000	DU PONT PHARMACEUTIC		ALS CO.					
B	AG	WO 01/92235	6 Dec 2001	DU PONT PHARMACEUTICALS CO.		ALS CO.					
	АН										
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)											
E	AI	CHAPMAN, P. F., <u>et al.</u> , "Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice", <i>Nature Neurosci.</i> (1999), <b>2</b> , 271-276									
Es	AJ	DAHLGREN, K. N., <u>et al.</u> , "Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability", <i>J. Biol. Chem.</i> (2002) <b>277</b> , 32046-32053									
É	AK	GÖTZ, J., <u>et al.</u> , "Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils", <i>Science</i> (2001) <b>293</b> , 1491-1495									
Sy	AL	LEWIS, J., <u>et al.</u> , "Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP", <i>Science</i> (2001), <b>293</b> , 1487-1491									
G	АМ	MCLEAN, C. A., <u>et al.</u> , "Soluble pool of Aβ-amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease", <i>Ann. Neurol.</i> (1999) <b>46</b> , 860-866									
E	AN	SEIFFERT, D.,F., <u>et al</u> ., "Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors", <i>J. Biol. Chem.</i> (2000) <b>275</b> , 34086-34091									
B	AO	SELKOE, D. J., "Alzheimer's Disease: Genes, Proteins, & Therapy", Physiol. Rev. (2001) 81, 741-766									
E	AP	SELKOE, D. J., "Mechanism of Alzheimer's Disease", Ann. Rev. Cell Biol. (1994) 10: 373-403									
B	AQ	THAL, D. R., <u>et al</u> ., "Two Types of Sporadic Cerebral Amyloid Angiopathy", <i>J. Neuropath. Exp. Neuro</i> . (2002) 61: 82-293									
8	AR	WALSH, D. M., <u>et al.</u> , "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation <i>in vivo</i> ", <i>Nature</i> (2002) <b>416</b> , 535-539									
B	AS	WOLFE, M. S., "Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential", J. Med. Chem. (2001) 44, 2039-2060									
	AT										
EXAMIN	IER/	and Sach	DATE (	CONSIDE	RED		<del> </del>				

\*EXAMINER: Initial of reference considered, Whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.